What we could do now: molecular pathology of gynaecological cancer

Charles Simon Herrington

What we could do now: molecular pathology of gynaecological cancer

Charles Simon Herrington

School of Medicine

Research output: Contribution to journal › Article › peer-review

Abstract

Gynaecological tumours exemplify many of the molecular paradigms of carcinogenesis. The clinical value of many of the molecular abnormalities present is now being tested and it is likely that the identification of at least some of these will become routine in the near future. This may help to refine diagnosis and guide treatment-for example, therapeutic vaccination for human papillomavirus related disease.

Original language	English
Pages (from-to)	222-224
Number of pages	3
Journal	Molecular Pathology
Volume	54
Publication status	Published - Aug 2001

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

gynaecology
cancer
papillomavirus
HUMAN-PAPILLOMAVIRUS
CERVICAL-CANCER
UTERINE LEIOMYOMAS
CARCINOMAS
MUTATIONS
PHASE

Cite this

@article{b00284b8dcfa41f9bc5c4eead88199cb,

title = "What we could do now: molecular pathology of gynaecological cancer",

abstract = "Gynaecological tumours exemplify many of the molecular paradigms of carcinogenesis. The clinical value of many of the molecular abnormalities present is now being tested and it is likely that the identification of at least some of these will become routine in the near future. This may help to refine diagnosis and guide treatment-for example, therapeutic vaccination for human papillomavirus related disease.",

keywords = "gynaecology, cancer, papillomavirus, HUMAN-PAPILLOMAVIRUS, CERVICAL-CANCER, UTERINE LEIOMYOMAS, CARCINOMAS, MUTATIONS, PHASE",

author = "Herrington, \{Charles Simon\}",

year = "2001",

month = aug,

language = "English",

volume = "54",

pages = "222--224",

journal = "Molecular Pathology",

issn = "1366-8714",

publisher = "BMJ Publishing Group",

}

TY - JOUR

T1 - What we could do now: molecular pathology of gynaecological cancer

AU - Herrington, Charles Simon

PY - 2001/8

Y1 - 2001/8

N2 - Gynaecological tumours exemplify many of the molecular paradigms of carcinogenesis. The clinical value of many of the molecular abnormalities present is now being tested and it is likely that the identification of at least some of these will become routine in the near future. This may help to refine diagnosis and guide treatment-for example, therapeutic vaccination for human papillomavirus related disease.

AB - Gynaecological tumours exemplify many of the molecular paradigms of carcinogenesis. The clinical value of many of the molecular abnormalities present is now being tested and it is likely that the identification of at least some of these will become routine in the near future. This may help to refine diagnosis and guide treatment-for example, therapeutic vaccination for human papillomavirus related disease.

KW - gynaecology

KW - cancer

KW - papillomavirus

KW - HUMAN-PAPILLOMAVIRUS

KW - CERVICAL-CANCER

KW - UTERINE LEIOMYOMAS

KW - CARCINOMAS

KW - MUTATIONS

KW - PHASE

UR - http://mp.bmjjournals.com/cgi/content/full/54/4/222

UR - https://www.scopus.com/pages/publications/0034902683

M3 - Article

SN - 1366-8714

VL - 54

SP - 222

EP - 224

JO - Molecular Pathology

JF - Molecular Pathology

ER -

What we could do now: molecular pathology of gynaecological cancer

Abstract

UN SDGs

Keywords

Other files and links

Fingerprint

Cite this